MRD testing is crucial for high-risk MM patients, aiding in early detection and treatment decisions, despite logistical and insurance barriers. Physicians primarily use MRD to monitor remission, ...
MRD refers to cancer cells remaining post-treatment, undetectable by standard imaging, indicating potential recurrence risk. MRD testing methods include flow cytometry and genetic tests, offering ...
April's vote of the FDA Oncology Drug Advisory Committee to support use of MRD-negative CR as an end point for accelerated approval represents a triumph of science, persistence, and collaboration, ...
Add Yahoo as a preferred source to see more of our stories on Google. This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive ...
Clinicians have long relied on clinical risk factors, imaging, and pathology to guide cancer surveillance and adjuvant treatment. However, even after curative-intent surgery and definitive therapy, ...
Molecular residual disease, or MRD, testing is emerging as a powerful tool in breast cancer, offering new visibility into what traditional imaging cannot detect. 1 MRD tests, like the Oncodetect® test ...
As oncology drug development becomes more biomarker-driven, the industry is rethinking what meaningful early insight looks like and how it can shape better decisions across the life cycle of a program ...
Minimal residual disease testing can offer psychological comfort to patients and survivors as well as insight into potential treatment strategies for care providers. Minimal residual disease, or MRD, ...
For patients with early-stage triple-negative breast cancer (TNBC), finishing chemotherapy and surgery should feel like the end of the hardest chapter. But for many, it marks the beginning of a ...
Myriad Genetics will present new data on its Precise MRD test for renal cell carcinoma at the AACR Annual Meeting. Myriad Genetics, Inc. announced that it will present new clinical data on its Precise ...
BioNexus Gene Lab Corp. (NASDAQ:BGLC) shares jumped 10% after the company announced strategic agreements with Fidelion Diagnostics to jointly commercialize VitaGuard, a next-generation liquid biopsy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results